Companies: 10,795·Total market cap: $144.5T
Vincerx Pharma, Inc.

Vincerx Pharma, Inc.

VINCOTCHealthcare● Active
$0.01
+$0.00(+3.54%)
Market Cap$68831
P/E Ratio—
52W High$1.43
52W Low$0.001
PE RatioMarket CapForecast

Vincerx Pharma, Inc. (VINC) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

vinc · pe ratio · data through Dec 31, 2024

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Vincerx Pharma, Inc. (VINC) measures how much investors pay for each dollar of the company's trailing earnings. VINC's current PE ratio of N/A is calculated by dividing its stock price of $0.01 by its TTM earnings per share of -$2.48.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31

Forward P/E
N/A
FY2026 est. EPS $-11.40
Based on 1 analyst
EPS (TTM)
-$2.48
TTM · diluted EPS
PEG Ratio
-0.00
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Vincerx Pharma, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2019 – 2024 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Vincerx Pharma, Inc.
Vincerx Pharma, Inc.You
VINC
$0MN/A—-$2.48
Aclarion, Inc.
Aclarion, Inc.
ACON
$2MN/A—-$13.60
Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc.
DRMA
$1MN/A—-$8.16
FOXO Technologies Inc.
FOXO Technologies Inc.
FOXO
$0MN/A—-$0.05
P3 Health Partners Inc.
P3 Health Partners Inc.
PIII
$40MN/A—-$45.26
Purple Biotech Ltd.
Purple Biotech Ltd.
PPBT
$0MN/A—-$10992.95
Revelation Biosciences, Inc.
Revelation Biosciences, Inc.
REVB
$4MN/A—-$14.36

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 6 of 6 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2024-12-31Latest
FY2024
—$-5.75—
2023-12-31
FY2023
—$-6.84—
2022-12-31
FY2022
—$-11.27—
2021-12-31
FY2021
—$-8.30—
2020-12-31
FY2020
—$-11.67—
2019-12-31
FY2019
—$-0.04—

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Vincerx Pharma, Inc. (VINC) measures how much investors pay for each dollar of the company's trailing earnings. VINC's current PE ratio of N/A is calculated by dividing its stock price of $0.01 by its TTM earnings per share of -$2.48.

PE Ratio = Stock Price ÷ EPS (TTM)
= $0.01 ÷ -$2.48 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.
Price historyFinancial statementsEarnings

Frequently asked questions

VINC pe ratio · 6 questions

VINC's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.01 and TTM EPS of -$2.48. Data sourced from Financial Modeling Prep via VINC's SEC 10-K and 10-Q filings.

VINC PE ratioWhat is VINC PE ratioCurrent PE ratio of VINCVINC PE ratio today

▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Vincerx Pharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09